Almirall, S.A.

Quick facts

Marketed products

• dapsone gel
• Tirbanibulin ointment 1%

Phase 3 pipeline

• dapsone gel vehicle · Dermatology
  Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties, reducing neutrophil migration and reactive oxygen species production.
• KX2-391 Ointment 1% · Dermatology
  KX2-391 is a Src kinase inhibitor that reduces skin inflammation and keratinocyte proliferation in atopic dermatitis.
• LAS106521 · Immunology / Dermatology
  LAS106521 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
• LAS41005 · Immunology / Dermatology
  LAS41005 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
• LAS41007 · Immunology/Dermatology
  LAS41007 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
• LAS41008 · Immunology
  LAS41008 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
• LASW1510 · Immunology / Dermatology
  LASW1510 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells.
• LASW1835 · Respiratory/Pulmonology
  LASW1835 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
• vehicle of LAS41007 · Respiratory
  LAS41007 is a small molecule inhibitor of the PDE4 enzyme.

Phase 2 pipeline

• Experimental: LAS 41004 dosage 1
  LAS 41004 is an investigational compound being developed by Almirall for dermatological or respiratory conditions, though its precise mechanism of action is not publicly disclosed.
• Experimental: LAS 41004 dosage 2
• Experimental: LAS 41004 dosage 3
• Experimental Tazarotene Gel
• LAD191
• LAD603
• LAS 41002
• LAS 41004
• LAS 41004 dosage 6
• LAS189961
• LAS189962
• LAS41003
• LAS41004
• LAS41007 b.i.d.
• LAS41007 o.d.

Phase 1 pipeline

• LAD106
• LAS40468
• LAS41004-IMP1
• LAS41004 IMP2
• LAS41004 IMP3
• LAS41004 IMP4
• LAS41004 IMP5
• LAS41004 IMP6

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Almirall, S.A. portfolio CI brief
• Almirall, S.A. pipeline updates RSS